nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2007 | Original Article

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

verfasst von: P. Antunes, M. Ginj, H. Zhang, B. Waser, R. P. Baum, J. C. Reubi, H. Maecke

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Gallium-68 is a metallic positron emitter with a half-life of 68 min that is ideal for the in vivo use of small molecules, such as [⁶⁸Ga-DOTA,Tyr³]octreotide, in the diagnostic imaging of somatostatin receptor-positive tumours. In preclinical studies it has shown a striking superiority over its ¹¹¹In-labelled congener. The purpose of this study was to evaluate whether third-generation somatostatin-based, radiogallium-labelled peptides show the same superiority.

Methods

Peptides were synthesised on solid phase. The receptor affinity was determined by in vitro receptor autoradiography. The internalisation rate was studied in AR4-2J and hsst-HEK-transfected cell lines. The pharmacokinetics was studied in a rat xenograft tumour model, AR4-2J.

Results

All peptides showed high affinities on hsst2, with the highest affinity for the Ga^III-complexed peptides. On hsst3 the situation was reversed, with a trend towards lower affinity of the Ga^III peptides. A significantly increased internalisation rate was found in sst2-expressing cells for all ⁶⁷Ga-labelled peptides. Internalisation into HEK-sst3 was usually faster for the ¹¹¹In-labelled peptides. No internalisation was found into sst5. Biodistribution studies employing [⁶⁷Ga-DOTA,1-Nal³]octreotide in comparison to [¹¹¹In-DOTA,1-Nal³]octreotide and [⁶⁷Ga-DOTA,Tyr³]octreotide showed a significantly higher and receptor-mediated uptake of the two⁶⁷Ga-labelled peptides in the tumour and somatostatin receptor-positive tissues. A patient study illustrated the potential advantage of a broad receptor subtype profile radiopeptide over a high-affinity sst2-selective radiopeptide.

Conclusion

This study demonstrates that ^67/68Ga-DOTA-octapeptides show distinctly better preclinical, pharmacological performances than the ¹¹¹In-labelled peptides, especially on sst2-expressing cells and the corresponding animal models. They may be excellent candidates for further development for clinical studies.

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef

Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas D, et al. [^99mTc]Demotate, a new ^99mTc-based [Tyr³]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 2002;29:742–53.PubMedCrossRef

Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. ^99mTc-EDDA/HYNIC-TOC: a new ^99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with ¹¹¹In-labelled octreotide derivatives. Eur J Nucl Med 2000;27:1318–25.PubMedCrossRef

Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [^99mTc/EDDA/HYNIC⁰]octreotide derivatives compared with [¹¹¹In-DOTA⁰,Tyr³, Thr⁸]octreotide and [¹¹¹In-DTPA⁰]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561–9.PubMed

de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA⁰,d-Phe¹,Tyr³]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368–71.PubMedCrossRef

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe¹]- and [¹²³I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.PubMedCrossRef

Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide—a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317–25.PubMed

Henriksen G, Schottelius M, Poethko T, Hauser A, Wolf I, Schwaiger M, et al. Proof of principle for the use of ¹¹C-labelled peptides in tumour diagnosis with PET. Eur J Nucl Med Mol Imaging 2004;31:1653–7.PubMedCrossRef

Wester H-J, Schottelius M, Scheidhauer K, Meisetschläger G, Herz M, Rau F, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel ¹⁸F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2002;30:117–22.PubMed

10.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, et al. Preparation and biological evaluation of copper-64-labeled Tyr³-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004;10:8674–82.PubMedCrossRef

11.

Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche E, et al. Tumor response and clincical benefit in neuroendocrine tumors after 7.4 GBq ⁹⁰Y-DOTATOC. J Nucl Med 2002;43:610–6.PubMed

12.

Otte A, Mueller-Brand J, Dellas S, Nitzsche E, Herrmann R, Maecke H. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417–8.PubMedCrossRef

13.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62S–66S.PubMed

14.

Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with ⁹⁰Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med 2003;30:207–16.CrossRef

15.

de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628–33.PubMedCrossRef

16.

Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, et al. ²¹³Bi-[DOTA⁰, Tyr³]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res 2006;12:897–903.PubMedCrossRef

17.

Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol 2000;12:368–77.PubMedCrossRef

18.

Maecke HR, Hofmann M, Haberkorn U. ⁶⁸Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46:172S–8S.PubMed

19.

Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [^67/68Ga] and [¹¹¹In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.PubMedCrossRef

20.

Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chemistry A European Journal 1999;5:1016–23.

21.

Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98:930–7.PubMedCrossRef

22.

Hofmann M, Maecke H, Börner A, Weckesser E, Schöffski P, Oei M, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7.PubMedCrossRef

23.

Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [⁶⁸Ga]-DOTA-D Phe¹-Tyr³-octreotide in comparison to [¹¹¹In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8.PubMedCrossRef

24.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of ⁶⁸Ga-DOTA-D-Phe¹-Tyr³-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46:763–9.PubMed

25.

Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Maecke HR, Eisenhut M, et al. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with ⁶⁸Ga-DOTATOC PET. Eur J Nucl Med Mol Imaging 2004;31:466.PubMedCrossRef

26.

Henze M, Schumacher T, Hipp P, Kowalski J, Becker D, Doll J, et al. PET imaging of somatostatin receptors using [⁶⁸Ga]DOTA-D-Phe¹-Tyr³-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053–6.PubMed

27.

Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke HR, et al. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using ⁶⁸Ga-DOTATOC PET and comparison with ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 2006;33:823–30.PubMedCrossRef

28.

Baum R, Niesen A, Leonhardi J, Wortmann R, Mueller D, Roesch F. Receptor PET/CT imaging of neuroendocrine tumours using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-Nal³ octreotide (DOTA-NOC): clinical results in 327 patients. Eur J Nucl Med Mol Imaging 2005;32 Suppl 1:S54–5.

29.

Roesch F, Zhernosekov K, Filosofov D, Jahn M, Jennewein M, Baum R, et al. Processing of Ge-68/Ga-68 generator eluates for labeling of biomolecules via bifunctional chelators. J Nucl Med 2006;47 Suppl 1:162P.

30.

Baum R, Schmücking M, Wortmann R, Müller M, Zhernosekov K, Rösch F. Receptor PET/CT using the Ga-68 labelled somatostatin analog DOTA-1-Nal³-octreotide (DOTA-NOC): clinical experience in 140 patients. Nuklearmedizin 2005;44:A57.

31.

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRef

32.

Win Z, Rahman L, Murrell J, Todd J, Al-Nahhas A. The possible role of ⁶⁸Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging 2006;33:506.PubMedCrossRef

33.

Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRef

34.

Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11:1136–45.PubMed

35.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef

36.

Tulipano G, Stumm R, Pfeiffer M, Kreienkamp HJ, Hollt V, Schulz S. Differential β-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem 2004;279:21374–82.PubMedCrossRef

37.

Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701–6.PubMedCrossRef

38.

Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with ¹⁸F-FDG PET. J Nucl Med 2006;47:793–6.PubMed

39.

Wild D, Maecke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. ⁶⁸Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2004;32:724.CrossRef

40.

Decristoforo C, von Guggenberg E, Haubner R, Rupprich M, Schwarz S, Virgolini I. Radiolabeling of DOTA-derivatised peptides with ⁶⁸Ga via a direct approach—optimization and routine clinical application. Nuklearmedizin 2005;44:A191–2.

41.

Hofmann M, Oei M, Boerner AR, Maecke H, Geworski L, Knapp WH, et al. Comparison of Ga-68-DOTATOC and Ga-68-DOTANOC for radiopeptide PET. Nuklearmedizin 2005;44:A58.

42.

Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 2006;47:502–11.PubMed

43.

Smith SV. Molecular imaging with copper-64. J Inorg Biochem 2004;98:1874–901.PubMedCrossRef

44.

Rossin R, Pan D, Qi K, Turner JL, Sun X, Wooley KL, et al. ⁶⁴Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 2005;46:1210–8.PubMed

45.

Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004;47:1465–74.PubMedCrossRef

Titel: Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
verfasst von: P. Antunes
M. Ginj
H. Zhang
B. Waser
R. P. Baum
J. C. Reubi
H. Maecke
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0317-x

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Brain reserve capacity in frontotemporal dementia: a voxel-based 18F-FDG PET study

Test–retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET

Reply

Bone and marrow imaging: do we know what we seeand do we see what we want to know?

M. Chinol, G. Paganelli (eds): Radionuclide peptide cancer therapy

Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer